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The retinoblastoma (RB) and p16ink4a tumor suppressors are believed to function in a linear pathway that
is functionally inactivated in a large fraction of human cancers. Recent studies have shown that RB plays a
critical role in regulating S phase as a means for suppressing aberrant proliferation and controlling genome
stability. Here, we demonstrate a novel role for p16ink4a in replication control that is distinct from that of RB.
Specifically, p16ink4a disrupts prereplication complex assembly by inhibiting mini-chromosome maintenance
(MCM) protein loading in G1, while RB was found to disrupt replication in S phase through attenuation of
PCNA function. This influence of p16ink4a on the prereplication complex was dependent on the presence of RB
and the downregulation of cyclin-dependent kinase (CDK) activity. Strikingly, the inhibition of CDK2 activity
was not sufficient to prevent the loading of MCM proteins onto chromatin, which supports a model wherein the
composite action of multiple G1 CDK complexes regulates prereplication complex assembly. Additionally,
p16ink4a attenuated the levels of the assembly factors Cdt1 and Cdc6. The enforced expression of these two
licensing factors was sufficient to restore the assembly of the prereplication complex yet failed to promote
S-phase progression due to the continued absence of PCNA function. Combined, these data reveal that RB and
p16ink4a function through distinct pathways to inhibit the replication machinery and provide evidence that
stepwise regulation of CDK activity interfaces with the replication machinery at two discrete execution points.
Due to their profound influence on tumorigenesis, substan-
tial effort has been directed at determining the function of the
p16ink4a and retinoblastoma (RB) tumor suppressors in cell
cycle control. Both tumor suppressors are inactivated in human
tumors, as achieved by genetic mutation, gene silencing, or
functional inactivation (6, 53, 63, 64). Biochemical and genetic
evidence demonstrate a functional connection between the two
tumor suppressors as part of a growth inhibitory network that
is disrupted in the majority of cancers.
p16ink4a is a cyclin-dependent kinase (CDK) inhibitor,
which arrests cells in G1 (38, 48) and is dependent on inhibition
of CDK4 and CDK2-associated activity. The influence of
p16ink4a on CDK4 is mediated by direct binding and involves
the disruption of CDK4/cyclin D interactions (57, 63). This
function of p16ink4a is required for its ability to inhibit cell
cycle progression and is disrupted in tumors which express
elevated levels of CDK4 (thus titrating p16ink4a) or in tumors
that harbor specific CDK4 mutations that compromise
p16ink4a association (28, 70). In addition, p16ink4a-mediated
disruption of the CDK4/cyclin D complex releases p27Kip1
and p21Cip1, leading to inhibition of CDK2 complexes (31,
65). This action is similarly required for p16ink4a-mediated
cell cycle inhibition and therefore differentiates the function of
p16ink4a from the genetic loss of CDK4 alone. A principle
target of CDK4 and CDK2 kinase complexes is RB, which is
inactivated by CDK-mediated phosphorylation in mid-G1 (6,
53, 62, 63, 65). The significance of RB as a downstream target
of p16ink4a was demonstrated by the finding that cells defi-
cient in RB function are resistant to p16ink4a-mediated cell
cycle inhibition (38, 44). Together, these studies suggest the
existence of a linear pathway wherein p16ink4a functions up-
stream of RB to regulate proliferation and tumorigenesis. This
model is supported by studies of human cancer wherein the
loss of RB and p16ink4a are mutually exclusive events (49, 52,
53, 64).
RB is the target of functional inactivation in a multitude of
tumors through a variety of different regulatory mechanisms.
For example, genetic mutation of RB is found in retinoblas-
toma, small-cell lung cancer, and osteosarcoma, while the
HPV-E7 protein targets RB function in cervical cancer (64).
RB functions as a transcriptional corepressor, which inhibits
the expression of critical gene products required for cell cycle
progression (11, 24). Paramount among these targets is cyclin
A, which has an exceedingly short half-life in the presence of
RB and is required for cell cycle progression (2, 39). The
repressive action of RB is manifest through interactions with
the E2F family of transcription factors and the recruitment of
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additional corepressors (e.g., histone deacetylase, SWI/SNF)
that facilitate the repression of E2F target genes (24). The
inactivation of RB via phosphorylation disrupts transcriptional
repression and enables the expression of E2F-regulated genes.
In this regard, loss of p16ink4a function is believed to dereg-
ulate G1 CDK activity, thus leading to aberrant phosphoryla-
tion/inactivation of RB. E2F-regulated genes are involved in
the activation of CDK2 (e.g., cyclin A) or DNA replication
(e.g., mini-chromosome maintenance protein 2 [MCM2]) (30,
56), and it is believed that E2F/RB activity serves a critical role
in coordinating entry into S phase (11).
DNA replication is a highly complex process containing mul-
tiple control mechanisms to ensure proper genomic duplica-
tion (7, 9, 18). As cells enter G1 from mitosis, Cdc6 and Cdt1
are independently recruited to a six-subunit origin recognition
complex (ORC), which is believed to be bound to origins
throughout the cell cycle (21, 67). These factors serve to recruit
MCMs 2 to 7, the members of the MCM hexameric complex
that load onto the origin (18, 19, 45, 50). The MCM complex
is necessary for replication initiation, and the disruption of any
one of the MCM family members results in the cessation of
DNA replication (36). MCM binding renders the origin com-
petent for the initiation of DNA replication and is termed the
prereplicative complex (preRC) (17–19, 45, 67). As cells
progress through G1 into early S, the preRC matures to facil-
itate the recruitment of functional replication complexes that
harbor DNA polymerases and associated processivity factors
(e.g., proliferating cell nuclear antigen [PCNA]) (17). As these
factors replicate the genome, the preRC is disrupted and re-
assembly is prevented by a variety of mechanisms which
largely target the activity of Cdc6 and Cdt1 (9, 17, 18). In
this manner, replication initiation at a given origin is re-
stricted to once per cell cycle. The coordination of these
events is believed to be reliant on the activation state of
CDK complexes that have both positive and negative roles
in DNA replication and the synthesis/degradation of critical
regulatory factors (16, 23, 40, 46).
Recent studies have shown that RB plays a specific role in
regulating DNA replication. Initially, it was observed that ex-
pression of constitutively active alleles of RB inhibits progres-
sion through S phase (3, 12, 60). Additional studies have shown
that loss of RB deregulates replication control, enabling DNA
replication to occur under inappropriate conditions (e.g., fol-
lowing DNA damage) (5, 34). The mechanism through which
RB mediates replication control remains a subject of intense
study, as both direct and indirect effects of RB on the replica-
tion machinery in S phase have been reported (10, 26, 32, 54,
66, 68). However, the activation of endogenous RB or the
introduction of constitutively active alleles of RB attenuates
CDK2 activity (through the downregulation of cyclin A) and
induces a loss of PCNA activity in S phase (3, 47, 60). Although
these studies connect RB to replication control, the influence
of p16ink4a on replication control has not been addressed.
Such an action by p16ink4a is highly relevant, since p16ink4a is
required for response to DNA damage and for mediating cell
cycle exit as a function of stresses that are associated with
aberrant cellular proliferation. Here, we demonstrate a distinct
effect of p16ink4a that influences the preRC at the level of
MCM loading, which is dependent on multiple G1 CDK activ-
ities. Together, these studies provide a new role for p16ink4a
and G1 CDK activity in regulating DNA replication, via a
mechanism not recapitulated by RB.
MATERIALS AND METHODS
Cell culture, transfections, and synchronizations. The following cell lines were
used based on their RB and p16ink4a statuses as summarized in Table 1. A2-4
cells express an active allele of RB, PSM-RB, under the control of doxycycline
(DOX) (60). U2OS human osteosarcoma cells express wild-type RB and CDK4
but are null for p16ink4a. Saos-2 human osteosarcoma cells express a mutant
nonfunctional RB but also express endogenous p16ink4a (1, 38). CV-1 cells
express wild-type RB, but p16ink4a is not detectable. MCF-7 breast carcinoma
cells express wild-type RB and are p16ink4a null (49). These cells were trans-
fected with plasmids encoding shRB or shDonor, and stable cells lines containing
an effective knockdown of RB expression were created. A2-4, U2OS, CV-1,
Saos-2, and MCF-7 cell lines were cultured in Dulbecco’s modified Eagle’s
medium supplemented with 10% heat-inactivated fetal bovine serum, 100
units/ml penicillin-streptomycin, and 2 mM L-glutamine at 37°C in 5% CO2. A2-4
cells harboring inducible expression of PSM-RB were supplemented with 1
mg/ml doxycycline. To activate the PSM-RB allele, cells were thoroughly washed
three times in phosphate-buffered saline (PBS) and cultured in medium lacking
DOX. Cells treated with roscovitine (Calbiochem) were incubated for 24 h at a
concentration of 10 M. The creation of shRB MCF-7 cells was described by
Bosco et al. (submitted for publication).
To synchronize cells in early S phase, 5 g/ml aphidicolin (APH; Calbiochem)
or 1 mM hydroxyurea (Sigma) was added to the medium for 16 h. To release cells
from the aphidicolin or hydroxyurea block, cells were washed three times with
PBS and fresh medium was added. To activate PSM-RB expression, A2-4 cells
were washed thoroughly with PBS to remove DOX and immediately placed in
fresh medium containing APH. Cells synchronized in mitosis were treated with
50 ng/ml nocodazole (NOC; Calbiochem) for 16 h. To release the nocodazole
block, cells were washed three times with PBS and cultured in fresh medium.
Protein stability was determined by transducing cells with the indicated ad-
enoviruses (see below), followed by cycloheximide addition at 24 h postinfection.
Cells were then subjected to Western blot analysis and bands quantitated by both
densitometry and the Odyssey infrared imaging system (Li-COR Biosciences).
Relative intensities were averaged and half-life values calculated. In addition to
using cycloheximide to determine protein half-lives, pulse chase labeling was
performed as previously described (2) (data not shown). Hemagglutinin (HA)-
Cdt1 was resolved by immunoprecipitation with anti-HA antibody.
U2OS and Saos-2 cells were transfected using plasmids encoding pCDNA
(vector-negative control), p16ink4a, CDK4, cyclin D1a, CDK4-R24C, NBCE, or
cyclin E. Histone H2B-green fluorescent protein (GFP) expression plasmid was
cotransfected to mark transfected cells. Transfections were performed using
FuGene (Roche) according to the manufacturer’s protocol. At 48 h posttrans-
fection, cells were harvested by trypsinization and fixed using 3.7% formaldehyde
in PBS or methanol at room temperature for 15 min.
Adenoviral infections. A2-4, CV-1, Saos-2, or U2OS cells (105) were seeded on
coverslips or in 10-cm dishes and infected with either Ad-GFP, Ad-p16ink4a,
Ad-GFP-Cdc6, Ad-HA-Cdt1, Ad-p21Cip1, or Ad-RBCDK at an approximate
multiplicity of infection of 10 for 24 h. The HA-tagged Cdt1 adenoviral construct
was generated by cloning a double-stranded oligonucleotide encoding two tan-
dem copies of the HA tag at the 5 end of the human Cdt1 cDNA in the
pENTR3C vector. Recombination with pAd/CMV/V5-DEST (Invitrogen) and
subsequent packaging in 293A cells were performed according to the manufac-
turer’s instructions. The RBCDK cDNA was excised from PCDNA-RBCDK
TABLE 1. Summary of cell lines used in this studya
Cell line RB status p16ink4a status
A2-4 (DOX) Wild type ND
A2-4 (DOX) PSM-RB induced ND
U2OS Wild type Null
Saos-2 Null Wild type
CV-1 Wild type ND
MCF-7 (shDonor) Wild type Null
MCF-7 (shRB) Knockdown Null
a ND, not detectable; Null, gene deletion/silencing/mutant; DOX, cultured
in the presence of DOX; DOX, cultured in the absence of DOX; shDonor,
containing shDonor; shRB, containing shRB.
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(15) and cloned into the pShuttleCMV vector (Qbiogene, Inc., Irvine, CA).
Recombination and packaging in HEK293 cells was carried out with standard
protocols. Viruses were purified by double cesium chloride gradient and viral
titers determined by standard approaches. In aphidicolin synchronization exper-
iments, cells were treated with aphidicolin (as described above) for 16 h before
infection with adenovirus for 24 h. In mitotic synchronizations, cells were treated
with NOC minutes before adenoviral infection. Cells were cultured for 16 h prior
to PBS wash and addition of fresh medium to initiate NOC release. Infection
efficiency was visualized by GFP fluorescence at 90 to 95%.
Biochemical fractionation and Western blotting. To isolate chromatin-bound
proteins, the protocol of Fujita et al. (25) was employed. Briefly, cells were
cultured in 15-cm plates, washed three times with PBS, trypsinized, and centri-
fuged at 5,000 rpm for 5 min at 4°C. Soluble proteins were then extracted with
ice-cold CSK buffer {10 mM PIPES [piperazine-N,N-bis(2-ethanesulfonic
acid)], pH 6.8, 100 mM NaCl, 300 mM sucrose, 1 mM MgCl2, 1 mM EGTA, 1
mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride} supplemented with
0.1% Triton X-100 for 15 min at 4°C. Extracted cells were centrifuged at 5,000
rpm for 5 min at 4°C, and the supernatant was removed. The pellet was then
reextracted and suspended in CSK. Total cell extracts were harvested as previ-
ously described (3). Lysates were resolved by sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis (SDS-PAGE) and transferred to Immobilon-P mem-
branes (Millipore). Membranes were incubated with the following antibodies:
anti-cyclin A (C19 mouse, H432 human; Santa Cruz), anti--tubulin (D10; Santa
Cruz), anti-PCNA (PC10; Santa Cruz), anti-MCM7 (141.2; Santa Cruz), anti-
ORC3 (1D6; Santa Cruz), anti-p16 (H156; Santa Cruz), anti-Lamin B (M20;
Santa Cruz), anti-Cdc6 (180.2; Santa Cruz), anti-MCM5 (C18; Santa Cruz),
anti-CDK4 (C22; Santa Cruz), and antigeminin (Fl209; Santa Cruz). Antibodies
against RB (J. Wang), RPA (M. Wold), Cdt1 (J. Cook), and MCM2 (I. Todorov)
were provided by the indicated investigators.
Immunofluorescence microscopy. For PCNA, MCM2, and MCM7 staining,
approximately 105 cells were seeded onto coverslips, washed with ice-cold PBS,
and fixed with methanol for 5 min. To visualize chromatin-tethered proteins,
coverslips were washed three times with PBS and extracted with a modified CSK
buffer as described above. Coverslips were washed with PBS and fixed in ice-cold
methanol for 5 min. The following antibodies were used for immunofluores-
cence: PCNA (PC-10; Santa Cruz) and MCM7 (141.2; Santa Cruz). Immuno-
fluorescence data are from three independent experiments, with at least 200 cells
scored per experiment. BrdU incorporation assays were performed as previously
described (33).
RT-PCR. RNA was harvested from U2OS cell cultures by using TRIzol ac-
cording to the manufacturer’s suggested protocols. Superscript reverse transcrip-
tase (RT; Invitrogen) and 5 g of total RNA were used to generate cDNAs with
random hexamer primers. PCR was carried out using the following primers:
5-GCG ATG ACA ACC TAT GCA ACA CTC-3 and 5-GAT GAC ATC CAT
CTC CCT TTC CCT-3 (human Cdc6), 5-AGG TCA GAT TAC CAG CTC
ACC ATC-3 and 5-ATT GAC TCA AGG CCT TCT CCA TCC-3 (human
Cdt1), and 5-GGT CAT CAA TGG GAA ACC CAT CAC-3 and 5-AGT ACT
GGT GTC AGG TAC GGT AGT-3 (for glyceraldheyde-3-phosphate dehydro-
genase).
Flow cytometry. Cells were harvested by trypsinization, fixed with ethanol, and
incubated with propidium iodide (3). Histograms represent 10,000 events.
RESULTS
p16ink4a and RB exert distinct effects on the DNA replica-
tion machinery. To investigate the coordinate action of the RB
and p16ink4a tumor suppressors in replication control, a pre-
viously characterized rat fibroblast cell line (A2-4) was utilized
(60). This cell line harbors the inducible expression of PSM-
RB, a phosphorylation site mutant allele of RB that is consti-
tutively active. As expected, the removal of doxycycline from
the medium resulted in the induced expression of PSM-RB,
and correspondingly, specific targets of RB-mediated tran-
scriptional repression, such as cyclin A, were downregulated at
the protein level (Fig. 1A). Under these same conditions, the
protein levels of PCNA were not attenuated, although cell
cycle progression was inhibited (Fig. 1A). To analyze the in-
fluence of PSM-RB on the replication machinery, a well-char-
acterized fractionation method was utilized, wherein actively
engaged replication proteins are tethered to chromatin, while
replication proteins not involved in replication are in a soluble
nucleoplasmic pool (25). As shown in Fig. 1B, the induction of
PSM-RB (via removal of doxycycline) had no influence on the
percentage of cells expressing PCNA (unextracted), which is
consistent with immunoblot analyses (Fig. 1A, left panel).
However, PSM-RB expression significantly attenuated the
chromatin-associated (extracted) pool of PCNA (Fig. 1B, left
panel, and Fig. 1E, lanes 3 and 4). In contrast, PSM-RB ex-
pression had minimal influence on both total and chromatin-
associated pools of MCM7 (Fig. 1B, right panel, and Fig. 1E,
lanes 1 to 4).
To investigate the action of p16ink4a in the same cellular
context, A2-4 cells were cultured in the presence of doxycycline
(preventing PSM-RB expression) and transduced with adeno-
viruses encoding either GFP (negative control) or p16ink4a.
Under these conditions, p16ink4a was robustly expressed
within 24 h (Fig. 1C, left panel). As expected, the effect of
p16ink4a was similar to that of PSM-RB, resulting in the spe-
cific downregulation of cyclin A but not PCNA protein levels
(Fig. 1C, left panel). Additionally, within this same time frame,
p16ink4a induced cell cycle arrest with a 2N DNA content (Fig.
1C, right panel). Together, these data are consistent with the
model wherein activation of RB and activation of p16ink4a
have comparable downstream effects on cell cycle control.
However, while p16ink4a expression did not influence total
MCM7 or PCNA levels, the chromatin association of both
factors was significantly inhibited (Fig. 1D and 1E). These data
demonstrate a new function for p16ink4a, which is distinct
from the conventional action of activated RB on the replica-
tion machinery.
While the replication machinery is highly conserved, the
unexpected result that RB and p16ink4a functions had distinct
effects on the association of MCM7 with chromatin led us to
analyze whether this phenomenon is apparent in other cellular
backgrounds. In U2OS (human osteosarcoma) cells, p16ink4a
expression resulted in the loss of both PCNA and MCM7 from
chromatin-associated fractions (Fig. 1F). In parallel to these
studies with p16ink4a, we utilized recombinant adenoviruses to
express the RBCDK allele (which is resistant to phosphory-
lation and therefore constitutively active) in U2OS cells (15).
While the protein was robustly expressed, downregulation of
PCNA (but not MCM) chromatin binding was observed (Fig.
1G, lanes 1 and 2). Thus, the distinct actions of RB and
p16ink4a are not restricted to a specific cell line or species.
Since DNA replication proceeds in a highly coordinated
manner, we sought to dissect the influence of p16ink4a on
other components of the replication machinery, both upstream
and downstream of MCM7. Initially, the retention of ORC3
with chromatin was assessed. Before MCM proteins can bind
and facilitate DNA replication, the ORC complex must be
bound to DNA (8, 67). As shown in Fig. 1F and G, neither
RBCDK nor p16ink4a influenced ORC3 expression or asso-
ciation with chromatin. Subsequent analyses of MCM2 and
MCM5 association with chromatin were performed, as these
proteins interact with MCM7 as part of the hexameric MCM
complex. Consistent with the results for MCM7, the loss of
MCM2 and MCM5 was observed in the chromatin-associated
protein in response to p16ink4a expression (Fig. 1F, lane 4).
Since formation of a functional preRC is required for the
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FIG. 1. p16ink4a disrupts PCNA and MCM7 chromatin association, whereas active RB targets only PCNA activity. (A) A2-4 cells were cultured
in the presence or absence of DOX (DOX and DOX, respectively) for 24 h. Left panel: cells were harvested, equal total protein amounts were
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subsequent recruitment of other factors to the replication ap-
paratus, the chromatin association of RPA70 was also as-
sessed, as this event is associated with the initiation of DNA
replication. Here, p16ink4a inhibited RPA retention (Fig. 1F,
lane 4). Combined, these results indicate that p16ink4a func-
tions to block the assembly of the MCM complex onto chro-
matin and thus inhibits subsequent downstream events in-
volved in DNA replication (i.e., RPA and PCNA engagement).
By contrast, RBCDK inhibited only the retention of PCNA
with chromatin and did not inhibit RPA chromatin association
(Fig. 1G), consistent with previously published data (20, 60).
Combined, these data indicate that the function of p16ink4a on
the replication machinery is distinct from that of RB and de-
fine an earlier point at which the tumor-suppressive pathways
intersect to control S phase.
p16ink4a signaling is compromised in a cell cycle phase-
specific manner. Given the significant influence of p16ink4a on
the replication machinery, the specific action of p16ink4a in S
phase was analyzed. While p16ink4a is a well-characterized
tumor suppressor, surprisingly little is known regarding its
function in controlling S-phase progression. To determine the
action of p16ink4a on the replication apparatus in S phase,
A2-4 cells were synchronized for 16 h in the presence of aphidi-
colin. This treatment inhibits S-phase progression and arrests
more than 85% of the cells in early S phase (not shown). The
cells were maintained in aphidicolin and transduced with ei-
ther GFP- or p16ink4a-encoding adenoviruses or cultured in
the absence of doxycycline. Cells were processed at 0, 4, 8, 16,
and 24 h postinfection or following doxycycline withdrawal and
assayed for MCM7 and PCNA chromatin association. Under
these conditions, PSM-RB induction did not influence MCM7
chromatin association but efficiently displaced PCNA from
chromatin (Fig. 2A). In contrast to the significant effect on an
asynchronous cell population, p16ink4a expression had mini-
mal influence on MCM7 chromatin association in S phase (Fig.
2B, left panel). Surprisingly, the levels of chromatin-bound
PCNA were also unchanged via p16ink4a expression in S-
phase cells (Fig. 2B, right panel). These findings were con-
firmed by immunoblot analyses performed on parallel cell cul-
tures (Fig. 2C). Therefore, although RB efficiently inhibited
PCNA activity in S-phase cell populations, p16ink4a had a
minimal effect in S-phase cultures. These results additionally
indicated that p16ink4a does not directly impact the DNA
replication fork or prevent late origin firing and suggested that
p16ink4a is incapable of signaling to downstream targets in S
phase. To test this idea, cyclin A protein levels were examined.
In asynchronous cells transduced with adenovirus encoding
p16ink4a or subjected to withdrawal of doxycycline for 24 h,
cyclin A levels were diminished dramatically (Fig. 2D, lanes 2
and 3). Induction of PSM-RB in S-phase cells also resulted in
the attenuation of cyclin A protein levels (Fig. 2D, lane 5).
However, with S-phase-synchronized cells, p16ink4a expres-
sion had minimal effect on cyclin A protein levels (Fig. 2D,
lane 6). These data were recapitulated with U2OS cells, where
expression of p16ink4a in asynchronous cultures dramatically
attenuated RB phosphorylation and cyclin A levels (Fig. 2E,
lane 2), whereas RB phosphorylation was not completely at-
tenuated and cyclin A expression was retained in aphidicolin-
synchronized cells (Fig. 2E, lane 4). To determine the direct
influence of p16ink4a on S-phase progression, cells were ini-
tially synchronized with aphidicolin and then transduced with
p16ink4a- or RBCDK-encoding adenoviruses and cultured
for 16 h to allow for accumulation of the encoded proteins.
Cells were then released from the aphidicolin block to deter-
mine the capacity of p16ink4a to mediate the repression of
cyclin A or inhibit S-phase progression as monitored by BrdU
incorporation. As shown in Fig. 2F, either in the presence of
aphidicolin or following a 4-h release, p16ink4a remained in-
competent for the downregulation of cyclin A. Under these
same conditions, while RBCDK expression efficiently inhib-
ited S-phase progression, p16ink4a expression had little influ-
ence on DNA synthesis (Fig. 2G).
To further investigate the effect of p16ink4a on the RB
pathway, CV-1 cells (either asynchronous proliferating or hy-
droxyurea synchronized) were transduced with either GFP- or
p16ink4a-encoding adenoviruses for the indicated time points
(Fig. 2H). While p16ink4a readily inhibited RB phosphoryla-
tion in cycling cells and suppressed the expression of cyclin A
levels, it was unable to efficiently influence RB phosphoryla-
tion in cells blocked in S phase (Fig. 2H, lanes 1 to 4 compared
to lanes 5 to 8). To explore the effect on cell cycle control,
BrdU incorporation assays were performed in asynchronous
and S-phase-synchronized cells. As expected, p16ink4a expres-
sion was able to efficiently arrest cycling cells. However,
resolved by SDS-PAGE, and the indicated proteins were detected by immunoblotting. Right panel: cells were harvested, fixed, stained with
propidium iodide, and processed for flow cytometry. Histograms are from 10,000 events. (B) A2-4 cells were cultured in the presence or absence
of DOX for 24 h. Cells were subjected to in situ extraction or control extraction (unextracted) and then fixed and immunostained for PCNA (left
panel) or MCM7 (right panel). Shown are the percentages of nuclei staining positive for PCNA or MCM7. (C) A2-4 cells cultured in the presence
of DOX were transduced with GFP- or p16ink4a (p16)-encoding adenoviruses and harvested at 24 h postinfection. Left panel: cells were harvested,
equal total protein amounts were resolved by SDS-PAGE, and the indicated proteins were detected by immunoblotting. Right panel: cells were
harvested, fixed, stained with propidium iodide, and processed for flow cytometry. Histograms are from 10,000 events. (D) A2-4 cells cultured in
the presence of DOX were transduced with GFP- or p16ink4a-encoding adenoviruses. At 24 h postinfection, cells were subjected to in situ
extraction or control extraction (unextracted) and then fixed and immunostained for PCNA (left panel) or MCM7 (right panel). Shown are the
percentages of nuclei staining positive for PCNA or MCM7. (E) A2-4 cells were cultured in the presence (lanes 1, 3, 5, 6, 7, and 8) or absence
(lanes 2 and 4) of DOX for 24 h or transduced with GFP (lanes 5 and 7)- or p16ink4a (lanes 6 and 8)-encoding adenoviruses and harvested at 24 h
postinfection. Equal total protein (lanes 1, 2, 5, and 6) or chromatin-associated protein (lanes 3, 4, 7, and 8) amounts were resolved by SDS-PAGE,
and the indicated proteins were detected by immunoblotting. (F) U2OS cells were transduced with GFP- or p16ink4a-encoding adenovirus and
harvested at 24 h postinfection. Equal total or chromatin-associated protein amounts were resolved by SDS-PAGE, and the indicated proteins were
detected by immunoblotting. (G) U2OS cells were infected with GFP- or RBCDK-encoding adenoviruses and harvested at 24 h postinfection.
Cells were subjected to in situ extraction, equal chromatin-associated protein amounts were resolved by SDS-PAGE, and the indicated proteins
were detected by immunoblotting.
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FIG. 2. p16ink4a does not disrupt the maintenance of the preRC in S phase. (A) A2-4 cells cultured in the presence of DOX were synchronized
in S phase with aphidicolin for 16 h. Cells were then cultured in the absence of DOX (DOX) for the indicated periods of time, subjected to in
situ extraction or control extraction (unextracted), fixed, and immunostained for MCM7 (left panel) or PCNA (right panel). Shown are the
percentages of nuclei staining positive for MCM7 or PCNA. (B) A2-4 cells cultured in the presence of DOX cells were synchronized in S phase
with aphidicolin for 16 h. Cells were then transduced with adenoviruses encoding p16ink4a (p16) and subjected to in situ extraction or control
extraction (unextracted) at the indicated times postinfection. Cells were then fixed and immunostained for MCM7 (left panel) or PCNA (right
panel). Shown are the percentages of nuclei staining positive for MCM7 or PCNA. (C) Left panel: A2-4 cells cultured in the presence of DOX
and either asynchronous (lanes 1 and 2) or arrested with aphidicolin (lanes 3 and 4) were transduced with GFP (lanes 1 and 3)- or p16ink4a (lanes
2 and 4)-encoding adenoviruses. At 24 h postinfection, cells were harvested, equal chromatin-associated protein amounts were resolved by
SDS-PAGE, and the indicated proteins were detected by immunoblotting. Right panel: either asynchronous (lanes 1 and 2) or aphidicolin-treated
(lanes 3 and 4) A2-4 cells were cultured in the presence (lanes 1 and 3) or absence (lanes 2 and 4) of DOX for 24 h. Cells were harvested, equal
amounts of chromatin-associated protein were resolved by SDS-PAGE, and the indicated proteins were detected by immunoblotting. (D) Either
asynchronous (lanes 1 to 3) or aphidicolin-synchronized (lanes 4 to 6) A2-4 cells were cultured in the absence of DOX (lanes 2 and 5) or transduced
with p16ink4a-encoding adenoviruses (lanes 3 and 6). Cells were harvested 24 h later, equal total protein amounts were resolved by SDS-PAGE,
and the indicated proteins were detected by immunoblotting. (E) U2OS cells asynchronously proliferating (lanes 1 and 2) or arrested with
aphidicolin (lanes 3 and 4) were transduced with GFP (lanes 1 and 3)- or p16ink4a (lanes 2 and 4)-encoding adenoviruses. Cells were harvested
at 24 h postinfection, equal amounts of total protein were resolved by SDS-PAGE, and the indicated proteins were detected by immunoblotting.
(F) U2OS cells were treated with aphidicolin for 16 h and then infected with either GFP- or p16ink4a-encoding adenoviruses for 24 h. Cells were
then either harvested or released from the aphidicolin block for 4 h and then harvested. Equal total protein amounts were resolved by SDS-PAGE,
and the indicated proteins were detected by immunoblotting. (G) U2OS cells were treated with aphidicolin for 16 h and then transduced with either
GFP-, RBCDK-, or p16ink4a-encoding adenoviruses for 24 h. Cells were then released from the aphidicolin block for 3 h and pulsed with BrdU
for 1 h. Coverslips were fixed and immunostained for BrdU incorporation. Data are from three independent experiments, with at least 200 cells
scored per experiment. (H) CV-1 cells, asynchronous (Asy) or hydroxyurea arrested (HU), were transduced with either GFP- or p16ink4a-encoding
adenoviruses for the indicated time points. Cells were harvested, equal total protein amounts were resolved by SDS-PAGE, and the indicated
proteins were detected by immunoblotting (top panel), immunostained for BrdU incorporation (middle panel), or subjected to in situ extraction
and immunostained for anti-PCNA (bottom panel). (I) CV-1 cells either asynchronously proliferating (data not shown) or arrested with APH and
transduced with adenoviruses encoding GFP, p16ink4a, or p21Cip1 (p21) for 16 h. Cells were harvested, equal total protein amounts were resolved
by SDS-PAGE, and the indicated proteins were detected by immunoblotting.
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p16ink4a had no effect on BrdU incorporation in cells that had
been released from the hydroxyurea block (Fig. 2H). This
failure of p16ink4a to signal in S phase held true for PCNA
chromatin engagement, as indicated in Fig. 2H. Together,
these results demonstrate that while active RB can function in
S-phase cells, p16ink4a signaling is disrupted both for the ac-
tivation of the RB pathway and for the disruption of preRC
function in this phase of the cell cycle.
Since p16ink4a directly inhibits CDK4, these results likely re-
flect a minimal role for this kinase in maintaining RB phospho-
rylation in S phase. To determine the corresponding influence of
CDK2 inhibition on RB phosphorylation, we assessed the effects
of enforced p21Cip1 expression. For these studies, CV-1 cells
were synchronized with aphidicolin and transduced with adeno-
viruses encoding GFP, p21Cip1, or both p16ink4a and p21Cip1.
In contrast with results observed with p16ink4a alone, p21Cip1
provoked RB dephosphorylation in the presence of aphidicolin
(Fig. 2I). Thus, CDK inhibitors differentially influence RB phos-
phorylation, dependent on cell cycle phase.
A functional RB pathway is required for p16ink4a-mediated
replicative inhibition. The above-described findings suggested
that while RB dephosphorylation/activation is not sufficient to
disrupt the preRC, it may be required for p16ink4a to signal to
CDK complexes. To determine the role of RB in mediating the
effects of p16ink4a on the replication machinery, the RB-de-
ficient osteosarcoma cell line Saos-2 was employed. As ex-
pected, Saos-2 cells lack the endogenous RB expression yet
express ample levels of endogenous p16ink4a and minimal
CDK4 (Fig. 3A). Saos-2 cells efficiently overproduced
p16ink4a following infection (Fig. 3B, left panel, lane 2); how-
ever, due to the absence of endogenous RB, there was a failure
to repress target genes, such as the cyclin A gene (Fig. 3B, left
panel, lane 2). In contrast, RBCDK expression was able to
repress cyclin A (Fig. 3B, right panel, lane 2), indicating that
the reconstitution of RB completes a functional RB pathway.
In these cells, the ectopic expression of p16ink4a failed to
disrupt the association of MCM7 with chromatin (Fig. 3C).
Therefore, these data suggest that the inhibition of preRC
activity is not due to a direct influence of p16ink4a on the
replication machinery but is dependent on RB signaling.
Since Saos-2 cells express high levels of endogenous
p16ink4a and relatively low levels of CDK4, reconstitution of
FIG. 3. Requirement of a functional RB pathway in preRC regula-
tion. (A) U2OS and Saos-2 cells were harvested, equal total protein
amounts were resolved by SDS-PAGE, and the indicated proteins were
detected by immunoblotting. (B) Left panel: Saos-2 cells were transduced
with GFP (lane 1)- or p16ink4a (lane 2)-encoding adenoviruses. At 24 h
postinfection, cells were harvested, equal total protein amounts were
resolved by SDS-PAGE, and the indicated proteins were detected by
immunoblotting. Right panel: Saos-2 cells were transduced with GFP
(lane 1)- or RBCDK (lane 2)-encoding adenoviruses. At 24 h postin-
fection, cells were harvested, equal total protein amounts were resolved by
SDS-PAGE, and the indicated proteins were detected by immunoblot-
ting. (C) Left panel: Saos-2 cells were transduced with GFP- or p16ink4a
(p16)-encoding adenoviruses. At 24 h postinfection, cells were subjected
to in situ extraction or mock extraction (unextracted), fixed, and immu-
nostained for MCM7. Shown are the percentages of nuclei staining pos-
itive for MCM7. Middle panels: Saos-2 cells were transduced with adeno-
viruses encoding GFP or RBCDK for 24 h. Cells were subjected to in
situ extraction, fixed, and immunostained for MCM7 or PCNA. The
percentages of cells staining positive for MCM7 or PCNA are shown.
Right panel: Saos-2 cells were transduced with adenovirus encoding GFP
or RBCDK for 24 h. Cells were then transfected with H2B-GFP or
H2B-GFP, CDK4, and cyclin D1 (cyc D1) 24 h postinfection. Cells were
subjected to in situ extraction, fixed, and immunostained for MCM7.
Percentages of nuclei positive for GFP and MCM7 are shown. Data are
from three independent experiments, with at least 200 cells scored per
experiment.
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FIG. 4. Coordinate action of p16ink4a inhibits MCM7 chromatin association. (A) A2-4 cells cultured in the presence of DOX were infected
with GFP- or p21Cip1 (p21)-encoding adenoviruses or treated with 10 M roscovitine (rvt). At 24 h posttreatment, cells were subjected to in situ
extraction or mock extraction (unextracted), fixed, and immunostained for MCM7 (left panel) or PCNA (right panel). Shown are the percentages
of cells staining positive for MCM7 or PCNA. (B) U2OS cells were treated with increasing doses of roscovitine as shown. At 24 h posttreatment,
coverslips were subjected to either mock (unextracted; not shown) or in situ extraction, fixed, and immunostained for PCNA or MCM7. (C) U2OS
cells were cotransfected with GFP-H2B and the indicated expression plasmids. At 48 h posttransfection, cells were subjected to mock (unextracted)
or in situ extraction, fixed, and immunostained for MCM7. The percentages of transfected (H2B-GFP-positive) cells staining positive for MCM7
are shown. Data are from three independent experiments, with at least 200 transfected cells scored per experiment. (D) U2OS cells were
cotransfected with H2B-GFP and either p16ink4a (p16); p16ink4a, cyclin D1 (cyc D1), and CDK4-R24C; cyclin E (cyc E); or NBCE for 48 h. Cells
were subjected to mock (unextracted) or in situ extraction, fixed, and immunostained for MCM7. The percentages of transfected (H2B-GFP-
positive) cells staining positive for MCM7 are shown. Data are from three independent experiments, with at least 200 transfected cells scored per
experiment.
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RB may be expected to restore the effects of p16ink4a in this
cell system. To test this idea, Saos-2 cells were transduced with
adenoviruses encoding GFP or RBCDK for 24 h. Strikingly,
RBCDK strongly attenuated chromatin-associated MCM7
and PCNA (Fig. 3C), specifically in Saos-2 cells. To determine
whether this specific influence of RBCDK on MCM7 loading
was due to the low levels of CDK4 activity in Saos-2 cells, the
influence of RBCDK was challenged with the ectopic expres-
sion of CDK4/cyclin D1. As shown in Fig. 3C (right panel),
CDK4/cyclin D1 expression efficiently restored MCM7 bind-
ing. Thus, these results indicate that Saos-2 cells are sensitive
to the effects of RB on the preRC due to the low levels of
CDK4 activity and support the idea that high levels of endog-
enous p16ink4a cooperate with RB.
G1 CDK inhibition through p16ink4a disrupts MCM load-
ing. The results described above suggest that while there is a
dependence on RB function, p16ink4a activity is distinct from
that of RB in regulating the preRC. Presumably, such an effect
could reflect the ability of p16ink4a to effectively target mul-
tiple CDK2 complexes, while RB effectively targets only cyclin
A-associated complexes (2, 39). To interrogate this possibility,
p21Cip1 was expressed in A2-4 cells. As shown in Fig. 4A
(right panel), p21Cip1 expression efficiently disrupted PCNA
chromatin association. This result indicates that loss of PCNA
tethering is an event common to both CDK inhibitors and RB
activation and was also observed with the expression of
p27Kip1 (not shown). However, p21Cip1 had minimal influ-
ence on MCM7 chromatin association (Fig. 4A, left panel).
Since p16ink4a and p21Cip1 both inhibit CDK2 activity, albeit
through different mechanisms, the influence of CDK2 activity
on MCM7 chromatin association was directly assessed using
the pharmacological CDK inhibitor roscovitine. Under condi-
tions of CDK2 inhibition, PCNA chromatin association was
maximally inhibited at a 20 M concentration (Fig. 4A and B).
In contrast, the levels of MCM7 were largely unchanged even
up to a 40 M concentration of roscovitine (Fig. 4B, left
panel). Together, these results indicate that p16ink4a harbors
an activity distinct from those of other CDK inhibitors in the
control of MCM7 chromatin association, likely through its
ability to coordinately inhibit CDK4 and CDK2 activity.
To test the influence of specific CDK/cyclin complexes in the
regulation of preRC function, cells were transiently transfected
with p16ink4a expression plasmids and plasmids encoding ei-
ther cyclin E (to restore CDK2 function) or CDK4 and cyclin
D1 (to restore CDK4 activity). In these studies, p16ink4a dis-
rupted the chromatin association of MCM7 in transfected cells
(Fig. 4C); however, the ectopic expression of either cyclin E or
a combination of both CDK4 and cyclin D1 restored MCM7
retention on chromatin. To determine whether CDK4 activity
is directly required for preRC assembly, R24C, a CDK4 mu-
tant that fails to bind p16ink4a, was utilized (70). As shown in
Fig. 4D, the effect of p16ink4a on MCM7 chromatin tethering
was overcome by CDK4-R24C expression, indicating that
CDK4 inhibition failed to block the p16ink4a-mediated inhi-
bition of MCM7 loading onto chromatin. While cyclin E ex-
pression can rescue MCM loading in the presence of p16ink4a,
we questioned the specific involvement of CDK2 activity in this
process. A mutant cyclin E that cannot bind CDK2 (nonbind-
ing cyclin E [NBCE]) (13) was incapable of reversing the in-
hibition of MCM7 chromatin association in the presence of
p16ink4a (Fig. 4D). Combined, these data indicate that the
coordinate inhibition of multiple G1 CDK complexes is re-
sponsible for the influence of p16ink4a on the preRC.
p16ink4a inhibits preRC assembly as cells progress out of
mitosis. The observation that p16ink4a failed to disrupt pre-
formed complexes in early S phase suggested that the influence
of p16ink4a is specific to the assembly of the preRC, which
occurs in early G1. To investigate the specific role of p16ink4a
in the assembly of the preRC, the maturation of the preRC as
cells progressed out of mitosis was investigated. Cells were
treated with nocodazole and then infected with GFP- or
p16ink4a-encoding adenoviruses. Cells were released from no-
codazole at 16 h postinfection and harvested at 1 h, 4 h, or 8 h
following release. Under these conditions, both GFP- and
p16ink4a-infected cells were efficiently synchronized in G2/M
and progressed into G1 following release (Fig. 5A). Following
treatment, the chromatin association of MCM7 was analyzed
kinetically (Fig. 5B). As expected, cells enriched in G2/M ex-
hibited minimal chromatin association of MCM7. However, as
GFP-infected cells entered into G1, there was a significant
increase in the engagement of MCM7 with chromatin at 1, 4,
and 8 h following mitotic exit (Fig. 5B, left panel). In contrast,
in cells expressing p16ink4a chromatin-associated MCM7, lev-
els did not increase significantly even by 8 h, when the majority
of cells were in G1 (Fig. 5B, right panel). Therefore, these data
FIG. 5. p16ink4a inhibits preRC formation upon mitotic exit.
(A) U2OS cells were treated with 50 ng/ml NOC or transduced with
adenovirus encoding p16ink4a and treated with NOC simultaneously
for 16 h. Cells were released from the nocodazole block for 0 h and 8 h
and harvested for flow cytometric analysis as indicated. (B) Cells were
subjected to in situ extraction or control extraction (unextracted) at the
indicated times following NOC release, fixed, and immunostained for
MCM7.
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demonstrate that p16ink4a expression specifically prevents
MCM loading and thus the formation of the preRC.
Direct inhibition of Cdc6 and Cdt1 by p16ink4a. Loading of
MCMs onto chromatin is dependent on the action of Cdc6 and
Cdt1. These factors are tightly regulated by multiple mecha-
nisms, including level of expression and the presence of the
inhibitory molecule geminin. Therefore, a possible explanation
for the observed inhibition of MCM7 chromatin binding is that
it was due to the downregulation or inactivation of Cdt1 or
Cdc6 or elevated expression of geminin. Initially, the influence
of RBCDK on Cdt1 and Cdc6 was assessed, and no alteration
of protein levels was observed (Fig. 6A, lane 2). These results
are consistent with the finding that MCM loading occurs in the
presence of dephosphorylated RB. Geminin levels were signif-
icantly downregulated by RBCDK (Fig. 6A, lane 2). Such a
result is consistent with previously published data on the reg-
ulation of geminin by the RB pathway (41, 71). By contrast,
p16ink4a initiated a significant reduction in the levels of both
Cdt1 and Cdc6 proteins (Fig. 6A, lane 4). To determine the
corresponding influence on RNA levels, RT-PCR was per-
formed on cells transduced with adenoviruses expressing GFP
or p16ink4a or treated with roscovitine. As shown in Fig. 6B,
RNA levels of Cdc6 and Cdt1 were inhibited by p16ink4a but
not by roscovitine, suggesting one mechanism through which
p16ink4a is inhibiting protein levels through transcriptional
repression. However, it has recently been demonstrated that
Cdc6 and Cdt1 protein levels are modulated as a function of
protein stability (4, 22, 37, 40, 55, 58). To determine the influ-
ence of p16ink4a on protein stability, we utilized adenovirus-
mediated expression of Cdc6 or Cdt1 as a substrate upon which
to monitor the effect of p16ink4a. At 24 h postinfection, cells
were treated with cycloheximide for 1, 2, and 5 h (Fig. 6C) and
protein levels were determined by Western blot analysis. Con-
sistent with a recent study (40), densitometry calculations
showed that the half-life of Cdc6 was reduced by approxi-
mately 50% with p16ink4a expression. Interestingly, we also
found that the Cdt1 protein half-life was reduced by 37% via
the expression of p16ink4a. Thus, p16ink4a regulates Cdc6 and
Cdt1 at the levels of both RNA level and protein stability.
Loss of Cdt1 and Cdc6 expression correlates with failure in
MCM loading. We have shown that p16ink4a signaling is com-
promised in S phase, resulting in a minimal effect on MCM
chromatin association. To determine the corresponding influ-
ence of p16ink4a on Cdc6 and Cdt1 in S phase, cells were
FIG. 6. p16ink4a inhibits preRC at the level of Cdc6 and Cdt1 regulation. (A) U2OS cells were transduced with either GFP (lanes 1 and 3)-,
p16ink4a (lane 4)-, or RBCDK (lane 2)-encoding adenovirus. At 24 h postinfection, cells were harvested, equal total protein amounts were
resolved by SDS-PAGE, and the indicated proteins were detected by immunoblotting. (B) U2OS cells were transduced with the indicated
adenoviruses or treated with roscovitine (rvt) for 24 h. RNA was then extracted using TRIzol according to the manufacturer’s protocol
(Invitrogen), and RT-PCR was performed using primers to amplify Cdc6, Cdt1, and GAPDH (glyceraldehyde-3-phosphate dehydrogenase).
(C) U2OS cells were transduced with adenoviruses encoding GFP or p16ink4a in combination with Cdc6 (left panels) or Cdt1 (right panels) for
24 h. Cells were then treated with cycloheximide (CHX) and harvested at the indicated time points. Lysates were harvested, equal total protein
amounts were resolved by SDS-PAGE, and the indicated proteins were detected by immunoblotting. Bands were quantitated using densitometry
(Metamorph software).
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synchronized with aphidicolin for 16 h and infected with
p16ink4a for 24 h. In this setting, enforced p16ink4a expression
had no effect on Cdc6 or Cdt1 in S phase (Fig. 7A), thus
correlating the loss of MCM chromatin association with the
presence of these loading factors. To determine whether RB
was similarly required for this activity, p16ink4a was intro-
duced into Saos-2 cells. Analysis of Cdc6 and Cdt1 revealed no
alteration upon p16ink4a expression (Fig. 7B). To further val-
idate this result, stable MCF-7 cell lines containing either an
empty short-hairpin RNA vector (shDonor) or short-hairpin
RNA directed against Rb (shRb) (Bosco et al., submitted)
were transduced with either GFP- or p16ink4a-encoding ad-
enoviruses. While the RB-proficient cells (shDonor) re-
sponded to p16ink4a expression by attenuating MCM7 chro-
matin binding, the RB-negative line (shRB) was refractory to
this effect of p16ink4a (Fig. 7D). Under these conditions,
p16ink4a similarly failed to influence Cdc6 and Cdt1 protein
levels in the absence of RB (Fig. 7C). Thus, RB is required for
the action of p16ink4a on both MCM loading and the attenu-
ation of Cdt1 and Cdc6. Combined, these results correlate the
influence of p16ink4a on Cdt1 and Cdc6 protein levels and the
inhibition of MCM loading.
Combined expression of Cdc6 and Cdt1 restores preRC
integrity in the presence of p16ink4a. To determine the action
of Cdc6 and Cdt1 in mediating the effects of p16ink4a, adeno-
viruses encoding either protein were employed. Using these
viruses, the expression of either Cdc6 or Cdt1 was efficiently
restored in the presence of p16ink4a (Fig. 8A). However, the
expression of either factor alone was not sufficient to restore
MCM7 chromatin association or trigger the engagement of
PCNA (Fig. 8B). In contrast, the coexpression of Cdc6 and
Cdt1 leads to the restoration of MCM7 chromatin binding in
the presence of p16ink4a (Fig. 8C and D). Under these same
conditions, PCNA failed to interact with chromatin (Fig. 8C).
Thus, the influence of p16ink4a on the preRC is specifically
manifest through Cdt1 and Cdc6 stability and additional facets
of CDK inhibition that contribute to the regulation of PCNA.
DISCUSSION
A number of studies have shown the actions of p16ink4a and
RB to be equivalent in cell cycle control. In most models,
p16ink4a blocks G1 CDK activity, thus maintaining the anti-
proliferative function of RB. Given this linear relationship, it
was assumed that p16ink4a and RB act in a linear pathway
to inhibit DNA replication. Here, we probed the mechanism
of p16ink4a-mediated replication control and found that
p16ink4a functions distinctly from RB in targeting the preRC.
Specifically, p16ink4a targets the assembly of preRCs at the
level of MCM loading (Fig. 9). This was observed with a
FIG. 7. Regulation of Cdc6 and Cdt1 by the RB pathway.
(A) U2OS cells were synchronized in S phase with APH for 16 h and
then transduced with adenoviruses encoding GFP or p16ink4a (p16)
for 24 h. Cells were harvested, equal total protein amounts were
resolved by SDS-PAGE, and the indicated proteins were detected by
immunoblotting. (B) Saos-2 cells were synchronized in S phase with
APH for 16 h and then transduced with adenoviruses encoding GFP or
p16ink4a for 24 h. Cells were harvested, equal total protein amounts
were resolved by SDS-PAGE, and the indicated proteins were de-
tected by immunoblotting. (C) MCF-7 cells stably expressing shDonor
or shRb were transduced with adenoviruses encoding GFP or p16ink4a
for 24 h. Cells were harvested, equal total protein amounts were
resolved by SDS-PAGE, and the indicated proteins were detected by
immunoblotting. (D) MCF-7 cells stably expressing shDonor or shRb
were transduced with adenoviruses encoding GFP or p16ink4a for
24 h. Cells were subjected to in situ extraction or mock extraction (data
for unextracted cells not shown), fixed, and immunostained for MCM7
(top panel) or PCNA (bottom panel). Shown are the percentages of
cells staining positive for MCM7 or PCNA.
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number of different MCM proteins and did not involve the
disruption of the ORC complex. The effect of p16ink4a is
not shared with RB, as observed either with activated alleles
or through activation/dephosphorylation of endogenous RB
(47). p16ink4a function is restricted to G1 and involves the down-
regulation of Cdc6 and Cdt1. These proteins are degraded or
become unstable as cells progress from S phase through mito-
sis (4, 37, 55), and the presented data suggest that p16ink4a
specifically compromises RNA and protein accumulation. In-
terestingly, Cdc6 has been shown to regulate the INK4 locus,
suggesting the possibility of a feedback loop through the co-
ordinate actions of these two factors (27). The p16ink4a tumor
suppressor is a potent transcriptional repressor functioning
through pocket proteins. Surprisingly, p16ink4a regulates the
expression of these proteins while RBCDK does not, reveal-
ing a key role for G1 CDK complexes in the control of MCM
loading. Such a hypothesis is supported by recent findings that
CDK activity contributes to the stabilization of Cdc6 (22, 40).
Thus, the difference in the actions of p16ink4a and RB on the
replication machinery is likely reflective of the manner in
which they target CDK/cyclins. p16ink4a targets CDK/cyclin
complexes through direct interaction with CDK4, thus mobi-
FIG. 8. Cdc6 and Cdt1 expression can rescue MCM7 tethering in the presence of p16ink4a (p16). (A) U2OS cells were transduced with either
Cdc6 (lanes 1 and 2)- or Cdt1 (lanes 3 and 4)-encoding adenoviruses in the presence (lanes 2 and 4) or absence (lanes 1 and 3) of p16ink4a-
encoding adenovirus. At 24 h postinfection, cells were harvested, equal protein amounts were resolved by SDS-PAGE, and the indicated proteins
were detected by immunoblotting. (B) Cells were transduced with either Cdc6 (lanes 1 and 2)- or Cdt1 (lanes 3 and 4)-encoding adenoviruses in
the presence (lanes 2 and 4) or absence (lanes 1 and 3) of p16ink4a-encoding adenovirus. Cells were subjected to in situ extraction 24 h
postinfection, equal chromatin-associated protein amounts were resolved by SDS-PAGE, and the indicated proteins were detected by immuno-
blotting. (C) Cells were transduced with GFP (lanes 1 and 4)-, p16ink4a (lanes 2 and 5)-, or p16ink4a-, Cdc6-, and Cdt1 (lanes 3 and 6)-encoding
adenovirus for 24 h. U2OS cells were then harvested or subjected to in situ extraction, equal chromatin-associated protein amounts were resolved
by SDS-PAGE, and the indicated proteins were detected by immunoblotting. (D) Cells were transduced with adenoviruses encoding the proteins
indicated. At 24 h postinfection, cells were subjected to in situ extraction, fixed, and immunostained for MCM7. Shown are the percentages of
nuclei staining positive for MCM7.
FIG. 9. Model of the RB pathway in coordinating DNA replica-
tion. p16ink4a prevents preRC formation by inhibiting the activity of
G1 CDK complexes, leading to a reduction in Cdc6 and Cdt1 protein
levels in G1. RB is negatively regulated by G1 CDK complexes yet also
plays a role in mediating the suppression of G1 CDK activity. RB acts
upon S-phase CDK complexes to inhibit the association of PCNA with
chromatin. This activity of RB is shared with other modalities that
inhibit CDK2 activity. p21, p21Cip1.
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lizing CDK2 inhibitors and preventing RB phosphorylation
(which further impinges on CDK2 activity) (63). As such, in
cells expressing p16ink4a, G1 CDK activity is maximally inhib-
ited, and as shown in Fig. 9, there is a subsequent failure to
load MCMs. The importance of overall downregulation of
CDK activity is demonstrated by the finding that the overpro-
duction of either cyclin E, CDK4/cyclin D1, or CDK4-R24C/
cyclin D1 can overcome the effect of p16ink4a on MCM load-
ing. Since CDK4-R24C specifically fails to interact with
p16ink4a and thus escapes inhibition, these results indicate
that CDK4 activity is critical for MCM loading. Conversely,
since a cyclin E mutant which does not mediate activation of
CDK2 fails to facilitate MCM loading in the presence of
p16ink4a, these data demonstrate that CDK2 kinase activity
also contributes to this process. Importantly, the inhibition of
CDK2 complexes alone does not recapitulate the effect of
p16ink4a on MCM loading. These results suggest that even
though CDK2 inhibition destabilizes Cdc6 (22, 40), the rela-
tively low levels of Cdc6 present under conditions of CDK2
inhibition are apparently sufficient to mediate MCM loading.
Therefore, we favor the model wherein the combined activity
of CDK complexes in early-G1 cells is required for the assem-
bly of preRC. Such a model takes into account the redundancy
of CDK complexes and suggests that the sum activity of the
complexes is required for MCM loading (51, 69). Presumably,
other INK4 family members would share this effect on DNA
replication due to their ability to inhibit both CDK4 and CDK2
activity. A critical aspect arising from this work is the influence
of p16ink4a loss on preRC assembly and Cdc6/Cdt1 expres-
sion. Using primary fibroblasts deficient for p16ink4a, no sig-
nificant effects on DNA replication have been observed (35,
61). Additionally, we have found no effect of p16ink4a loss on
the expression of MCMs, Cdt1, and Cdc6 (data not shown).
Thus, we would speculate that the influence of p16ink4a loss
on replication control will be manifest only under specific con-
ditions wherein p16ink4a is induced and required for cell cycle
exit (as occurs during prolonged passage or specific cellular
stresses). Based on recent data indicating that p16ink4a induc-
tion occurs in preneoplastic lesions as a potential barrier to
cancer (14, 59), such lesions arising in p16ink4a-proficient and
-deficient mice would represent an ideal setting for defining
the involvement of p16ink4a loss in replication control in a
highly relevant model.
The role of RB in the regulation of preRC, downstream of
p16ink4a, could represent distinct effects on CDK2 activity.
First, the loss of RB substantially deregulates the expression
levels of cyclins E and A (29). Thus, the absence of RB could
simply dampen the ability of p16ink4a to sufficiently inhibit
CDK2 activity. Second, as we show here, the loss of RB pre-
vents the downregulation of cyclin A, which would further
compromise the ability of p16ink4a to inhibit CDK2 activity.
Thus, RB indirectly facilitates the action of p16ink4a on MCM
loading in G1 by limiting G1 CDK activity (Fig. 9). Corre-
spondingly, this G1 CDK activity targets RB via phosphoryla-
tion (Fig. 9). In contrast with the effect of p16ink4a in G1, RB
plays a distinct role in targeting DNA replication in S phase.
Cells or tissues deficient in RB exhibit a deregulated S phase
and harbor a propensity for overreplication of the genome (5,
42, 43). RB targets replication in S phase via downregulation of
PCNA activity, which is dependent on the efficient downregu-
lation of cyclin A protein levels and diminished CDK2 activity
(60). This influence of RB is recapitulated by CDK inhibitors
and pharmacological inhibitors of CDK2 (Fig. 9). The action of
p16ink4a in S phase had heretofore not been explored. How-
ever, as shown here, p16ink4a is not able to efficiently lead to
the dephosphorylation of RB or the downregulation of cyclin
A expression in S-phase-synchronized cells. Thus, while
p16ink4a can impinge upon the replication machinery, this
effect is restricted to G1. In contrast, RB functionality is main-
tained in S phase, and the regulation of RB phosphorylation in
S phase must be under controls distinct from those elicited by
p16ink4a. As such, it would be predicted that in p16ink4a-
deficient cells, RB-dependent control over S phase remains
intact. However, signals that act through p16ink4a in G1 (e.g.,
response to oncogenic stresses that induce senescence) would
be expected to have profound impacts on the replication ma-
chinery by targeting the preRC.
Significant emphasis has been placed on determining the
action of CDK in coordinating cell cycle progression. Our data
indicate that there are two distinct facets of S phase which are
regulated by CDK activity. The first occurs in early G1, wherein
the accumulation of Cdt1 and Cdc6 is dependent on G1 CDK
complexes (Fig. 9). The second is in S phase, wherein the
activity of PCNA is dependent on the availability of CDK2
complexes (Fig. 9). Strikingly, both of these processes are co-
ordinated through the action of the interrelated p16ink4a and
RB tumor suppressors.
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